Over the course of my four years with Avalo Therapeutics (formerly Cerecor, Inc) my responsibilities included running the commercial business, strategic marketing, product development, business development, investor relations, public relations, corporate marketing, and information technology. Successfully rebranded the company to the investment community and raised over $100 million in capital to support pipeline asset development.Accomplishments:Raised >$100M in capital thru confidentially marketed public offerings (CMPO)Instituted product development planning for pipeline assetsDeveloped IT Infrastructure with 0- to 5-year horizonRenamed and rebranded organization from Cerecor to Avalo Therapeutics, including internal and external marketingAligned Leadership Team to evolved organizational vision and values Developed go-to-market access strategy for near-term pipeline assetsManaged sales and distribution of commercially approved asset

Developed long-range strategic operating planAdvanced corporate strategy and investor communicationsBuilt commercialization and launch plans for CERC-800 family of pipeline assetsDeveloped brand strategy and marketing plans for 8 in-line brandsExecuted corporate communications and public relations Rebranded entire organization

Principal at NSCI Group- NSCI Group - A privately held Strategic Communications Company that develops Brand Strategy and delivers Tactical Execution in Specialty Markets across the Bio-Pharmaceutical area. Centers of Excellence: Brand Strategy Design, Digital Media, KOL Development, Medical Communications, Sales Training, Advisory Boards and Meeting Production.Responsible for new business development Focus on developing brand strategies to accelerate growthEngagements included Johnson & Johnson, Actelion, InterMune, Pulse Therapeutics, Covidien, Medimmune, Incyte, Bayer, EDGE Therapeutics, and Portola Therapeutic areas included thrombosis, pulmonary hypertension, oncology, pain, infectious disease, and stroke Developed positioning, messaging and launch of revolutionary medical education platform MedEd OntheGoGenerated over $25 million in sales during ownershipLaunch of Andexxa® for Factor Xa associated bleedingLaunch of Bevyzza® for prevention of DVT in high-risk hospitalized patients

Executive leader responsible for overseeing all commercial activities across Specialty Pharmaceuticals. Responsibilities include Sales, Marketing, Operations, and Managed Care as well as supporting the development of pipeline assetsExceeded 2012 Business Plan by $30MGenerated >$150M in net sales Generated >$45M in operating incomeBrought franchise into profitability within 18 months of product launchesDelivered year-on-year growth of both brands >100%Responsible for integration of CNS Therapeutics acquisitionLaunched 2 co-promotion products to expand pain franchise Led 260-person Sales organization / 14-person Marketing organizationOversaw 12-person Sales Operations / 8-person Managed Care organization

Vice President of in-line Brand Marketing. P&L responsibility for two Pediatric Infectious Disease products in the Biologic and Vaccine Category.Responsible for Global Infectious Disease franchise Interim Vice President, Commercial Operations, with Business Unit at 119% to plan Q2 2010P&L responsibility for 2 Infectious Diseases therapeutic areas (flu and respiratory syncytial virus [RSV])Exceeded 2009 global revenue to $1.75B with $191M in management net incomeExceeded domestic FluMist® forecast at 105% to plan; 45% growthPromoted in 2009 to lead 4 teams comprising 18 marketing professionals across Brand Marketing, Access Marketing, and International MarketingManaged operating budget >$50MLed Global RSV franchise; delivered $1.2B in global sales with $32M operating budget from 2007-2009Responsible for OUS distribution agreement with Abbott International exceeding $700M in sales and $350M in management net income

Responsible for Remicade® and New Molecular Entities for OUS market developmentExceeded 2005 sales/revenue targets, growing sales to $1.052B (+30% PY)Marketing strategist in EU markets with distribution partner Schering-Plough Responsible for launch strategies in ChinaMarketing liaison with distribution partner, Tanabe Inc., Japan

Directed Remicade® worldwide marketing for rheumatoid arthritis (RA)P&L responsibility for RA indication of Remicade2003 100% to business plan $1.045B; 25% growth over 20022002 exceeded forecast by $214M; 134% to planGrew sales by 75% over prior year; $482M to $840MResponsible for market expansion and product differentiation strategiesLed integration of strategies with global partner Schering-PloughImplemented Integration of strategies with Field Sales, Training, and Medical Affairs Personnel responsibilities for brand team; 4 direct reports/2 second-line managersAlignment responsibilities for $80M A&P budget